SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Belanger who wrote (304)1/23/1997 6:46:00 PM
From: Brad C. Dunlap   of 1762
 
Hi Richard, in Coulter's phase I results that were published in the July 1996 Journal of Clinical Oncology. Patients were first given a trace-labled doses of 131 labled anti B1[15 to 20 mg, 5mCi] to assess radiolabled antibody biodistribution, and then a radioimmunotherapeutic dose[ 15 to 20 mg] labled with a quantity of 131 that would deliver a specified centigray dose of whole-body radiation predicited by the tracer dose. Whole body radiation doses were escalated from 25 to 85cGy. Hematologic toxicity was dose-limiting, and 75 cGy was established as the maximally tolerated whole body radiation dose. 28 patients received radioimmunotherapeutic doses of 34 to 161 mCi. Since I'm not in the medical profession I trust that this answers your question.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News